Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. (PYXS) is a clinical-stage biopharmaceutical company pioneering antibody-drug conjugates (ADCs) targeting components of the tumor microenvironment to address challenging cancers. This page provides investors and researchers with a comprehensive repository of official announcements, clinical trial updates, and strategic developments.
Access timely updates on PYX-201 progress, partnership agreements, and regulatory milestones. Our curated collection includes earnings reports, preclinical data disclosures, and management commentary – all essential for evaluating the company’s position in oncology innovation.
Key content categories include ADC platform advancements, clinical trial phase transitions, and scientific collaborations. Users will find verified information on therapeutic mechanisms targeting extracellular matrix proteins like EDB+FN, a focus area distinguishing Pyxis in immuno-oncology.
Bookmark this page for streamlined access to material events affecting Pyxis Oncology’s trajectory. Check regularly for new developments in their pipeline programs and evidence-based analysis of therapeutic candidates.
Pyxis Oncology (PYXS) reported a Q2 net loss of $25.6 million, or $(0.79) per share, compared to $(5.54) per share a year prior. As of August 15, 2022, the company had a cash balance of $207 million, providing runway through H2 2024. Key highlights include a focus on advancing two lead programs: PYX-201, an ADC, and PYX-106, an mAb, with IND filings expected in 2022. PYXS has paused two programs (PYX-203 and PYX-102) and ceased development of PYX-202. The company appointed Dr. Rachel Humphrey to its Board, enhancing its expertise in oncology drug development.
On July 1, 2022, Pyxis Oncology (Nasdaq: PYXS) announced the granting of restricted stock units totaling 61,360 shares and stock options for 76,701 shares to four new employees. This grant falls under the 2022 Inducement Plan and complies with Nasdaq rules. The stock options feature an exercise price of $2.44, corresponding to the closing share price on the grant date. Vesting occurs over four years, with 25% vesting after one year, and the remaining shares vest monthly thereafter. This initiative aims to bolster the company’s talent and support its development of therapeutics for hard-to-treat cancers.
Pyxis Oncology, Inc. (Nasdaq: PYXS), focused on next-generation cancer therapeutics, will present at the H.C. Wainwright Preclinical Cancer Drug Discovery conference. The presentation, featuring Lara Sullivan, M.D., and Jay Feingold, M.D., Ph.D., will be available on-demand starting at 9:00 a.m. ET on June 29, 2022. A webcast will also be accessible on the Pyxis Oncology investor relations site and will be archived for 90 days.
Founded in 2019, Pyxis develops antibody drug conjugates and monoclonal antibodies to tackle challenging cancers.
Pyxis Oncology (Nasdaq: PYXS) announced that CEO Lara Sullivan and the management team will present at two upcoming investor conferences.
- H.C. Wainwright Global Investment Conference: May 24, 2022, at 7:00 a.m. ET; format includes pre-recorded presentation and virtual meetings.
- Jefferies Healthcare Conference: June 8, 2022, at 2:00 p.m. ET; format includes live presentation and 1:1 meetings in New York.
Webcasts of the presentations will be available on the company's investor relations site and can be replayed for 90 days.
Pyxis Oncology (Nasdaq: PYXS) reported its Q1 2022 financial results on May 13, 2022, ending the quarter with approximately $247 million in cash. The company anticipates filing INDs for several drug candidates in H2 2022 and H2 2023. R&D expenses decreased to $20.1 million from $32.8 million in Q1 2021, while G&A expenses rose to $11.3 million due to increased personnel costs. The net loss was $31.4 million or $0.97 per share, an improvement compared to the $36.8 million loss in the same period last year.
Pyxis Oncology (Nasdaq: PYXS) will have its President and CEO, Lara Sullivan, participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 2:40 p.m. PT in Las Vegas, Nevada. The event will be available via webcast on the Investors section of the Pyxis Oncology website. A replay will be archived for 90 days. Pyxis Oncology is dedicated to developing next-generation therapeutics targeting challenging cancers, with a focus on antibody drug conjugates and monoclonal antibodies to enhance treatment efficacy.
Pyxis Oncology has announced a leadership change with Ronald Herbst, Ph.D., stepping down as Chief Scientific Officer, effective April 12, 2022. Jan Pinkas, Ph.D., previously Senior VP of Preclinical Research, has been promoted to this role. The transition comes as the company prepares for IND filings for Anti-EDB (PYX-201) and Anti-Siglec-15 (PYX-106) in the second half of 2022, signaling a commitment to advancing its clinical programs and therapeutics aimed at treating difficult cancers.
Pyxis Oncology announced promising preclinical data for PYX-106, an anti-Siglec-15 monoclonal antibody, presented at the 2022 AACR Annual Meeting. The findings suggest that PYX-106 effectively inhibits tumor growth in a mouse model while demonstrating a long half-life in non-human primate studies. This candidate aims to expand treatment options for patients with tumors resistant to current therapies. The IND filing is anticipated in the second half of 2022.
Pyxis Oncology has obtained exclusive rights to develop and commercialize Biosion's anti-Siglec-15 monoclonal antibody, BSI-060T, now known as PYX-106. The deal includes a $10 million upfront fee for Biosion, with potential milestone payments totaling $222.5 million and royalties on future sales. Pyxis plans to submit an IND to the FDA by late 2022 and initiate a Phase 1 trial. The new addition is expected to address significant medical needs in solid tumors, primarily non-small cell lung cancer and head and neck cancer.
Pyxis Oncology (PYXS) has expanded its immuno-oncology pipeline with the in-licensing of anti-Siglec-15 (now PYX-106) from Biosion and the introduction of its first internally developed candidate, anti-KLRG1 (PYX-102). The company reported cash reserves of approximately $253 million, expected to fund operations through Q3 2024, and aims to file INDs for various candidates in the upcoming years. R&D expenses rose to $51.1 million in 2021, reflecting investments in multiple antibody-drug conjugates. The net loss was $76 million, primarily due to these developments.
FAQ
What is the current stock price of Pyxis Oncology (PYXS)?
What is the market cap of Pyxis Oncology (PYXS)?
